Vitals & Signals
The FDA is quietly rewriting the fundamental contract of clinical AI regulation — moving from a pre-market permission slip to a post-market surveillance regime — and every founder, investor, and clinician in this industry needs to understand what that means before the framework lands.
6 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de Vitals & Signals!